Catalyst
Slingshot members are tracking this event:
Phase 2 long-term data of Iovance's(IOVA) LN-144 - lifileucel in Refractory metastatic melanoma to be presented at AACR meeting April 10, 2021, 3:30 PM
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| IOVA | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Apr 09, 2021
Occurred Source:
https://ir.iovance.com/news-releases/news-release-details/iovance-biotherapeutics-announces-clinical-data-updates-0
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Ln-144, Refractory Metastatic Melanoma, Aacr
